The CAIRO4 study: The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer-a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)

Jorine 't Lam-Boer, Linda Mol, Cornelis Verhoef, Anton F J de Haan, Mette Yilmaz, Cornelis J A Punt, Johannes H W de Wilt, Miriam Koopman

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Resumé

BACKGROUND: There is no consensus regarding resection of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastatic colorectal cancer (CRC). A potential benefit of resection of the primary tumour is to prevent complications of the primary tumour in later stages of the disease. We here propose a randomized trial in order to demonstrate that resection of the primary tumour improves overall survival.

METHODS/DESIGN: The CAIRO4 study is a multicentre, randomized, phase III study of the Dutch Colorectal Cancer Group (DCCG). Patients with synchronous unresectable metastases of CRC and few or absent symptoms of the primary tumour are randomized 1:1 between systemic therapy only, and resection of the primary tumour followed by systemic therapy. Systemic therapy will consist of fluoropyrimidine-based chemotherapy in combination with bevacizumab. The primary objective of this study is to determine the clinical benefit in terms of overall survival of initial resection of the primary tumour. Secondary endpoints include progression free survival, surgical morbidity, quality of life and the number of patients requiring resection of the primary tumour in the control arm.

DISCUSSION: The CAIRO4 study is a multicentre, randomized, phase III study that will assess the benefit of resection of the primary tumour in patients with synchronous metastatic CRC.

TRIAL REGISTRATION: The CAIRO4 study is registered at clinicaltrials.gov (NCT01606098).

OriginalsprogEngelsk
ArtikelnummerTPS3630
TidsskriftJournal of Clinical Oncology
Vol/bind33
Udgave nummer15 Suppl.
ISSN0732-183X
StatusUdgivet - 2015
BegivenhedASCO Annual Meeting 2015 - Chicago, USA
Varighed: 29 maj 20152 jun. 2015

Konference

KonferenceASCO Annual Meeting 2015
LandUSA
ByChicago
Periode29/05/201502/06/2015

Fingerprint

Colorectal Neoplasms
Neoplasm Metastasis
Neoplasms
Survival
Combination Drug Therapy
Disease-Free Survival
Therapeutics
Quality of Life
Morbidity

Citer dette

@article{6a0f1b30382f432dae1032b422b4cb6e,
title = "The CAIRO4 study: The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer-a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)",
abstract = "BACKGROUND: There is no consensus regarding resection of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastatic colorectal cancer (CRC). A potential benefit of resection of the primary tumour is to prevent complications of the primary tumour in later stages of the disease. We here propose a randomized trial in order to demonstrate that resection of the primary tumour improves overall survival.METHODS/DESIGN: The CAIRO4 study is a multicentre, randomized, phase III study of the Dutch Colorectal Cancer Group (DCCG). Patients with synchronous unresectable metastases of CRC and few or absent symptoms of the primary tumour are randomized 1:1 between systemic therapy only, and resection of the primary tumour followed by systemic therapy. Systemic therapy will consist of fluoropyrimidine-based chemotherapy in combination with bevacizumab. The primary objective of this study is to determine the clinical benefit in terms of overall survival of initial resection of the primary tumour. Secondary endpoints include progression free survival, surgical morbidity, quality of life and the number of patients requiring resection of the primary tumour in the control arm.DISCUSSION: The CAIRO4 study is a multicentre, randomized, phase III study that will assess the benefit of resection of the primary tumour in patients with synchronous metastatic CRC.TRIAL REGISTRATION: The CAIRO4 study is registered at clinicaltrials.gov (NCT01606098).",
author = "{'t Lam-Boer}, Jorine and Linda Mol and Cornelis Verhoef and {de Haan}, {Anton F J} and Mette Yilmaz and Punt, {Cornelis J A} and {de Wilt}, {Johannes H W} and Miriam Koopman",
year = "2015",
language = "English",
volume = "33",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "15 Suppl.",

}

The CAIRO4 study : The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer-a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG). / 't Lam-Boer, Jorine; Mol, Linda; Verhoef, Cornelis; de Haan, Anton F J; Yilmaz, Mette; Punt, Cornelis J A; de Wilt, Johannes H W; Koopman, Miriam.

I: Journal of Clinical Oncology, Bind 33, Nr. 15 Suppl., TPS3630, 2015.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

TY - ABST

T1 - The CAIRO4 study

T2 - The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer-a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)

AU - 't Lam-Boer, Jorine

AU - Mol, Linda

AU - Verhoef, Cornelis

AU - de Haan, Anton F J

AU - Yilmaz, Mette

AU - Punt, Cornelis J A

AU - de Wilt, Johannes H W

AU - Koopman, Miriam

PY - 2015

Y1 - 2015

N2 - BACKGROUND: There is no consensus regarding resection of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastatic colorectal cancer (CRC). A potential benefit of resection of the primary tumour is to prevent complications of the primary tumour in later stages of the disease. We here propose a randomized trial in order to demonstrate that resection of the primary tumour improves overall survival.METHODS/DESIGN: The CAIRO4 study is a multicentre, randomized, phase III study of the Dutch Colorectal Cancer Group (DCCG). Patients with synchronous unresectable metastases of CRC and few or absent symptoms of the primary tumour are randomized 1:1 between systemic therapy only, and resection of the primary tumour followed by systemic therapy. Systemic therapy will consist of fluoropyrimidine-based chemotherapy in combination with bevacizumab. The primary objective of this study is to determine the clinical benefit in terms of overall survival of initial resection of the primary tumour. Secondary endpoints include progression free survival, surgical morbidity, quality of life and the number of patients requiring resection of the primary tumour in the control arm.DISCUSSION: The CAIRO4 study is a multicentre, randomized, phase III study that will assess the benefit of resection of the primary tumour in patients with synchronous metastatic CRC.TRIAL REGISTRATION: The CAIRO4 study is registered at clinicaltrials.gov (NCT01606098).

AB - BACKGROUND: There is no consensus regarding resection of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastatic colorectal cancer (CRC). A potential benefit of resection of the primary tumour is to prevent complications of the primary tumour in later stages of the disease. We here propose a randomized trial in order to demonstrate that resection of the primary tumour improves overall survival.METHODS/DESIGN: The CAIRO4 study is a multicentre, randomized, phase III study of the Dutch Colorectal Cancer Group (DCCG). Patients with synchronous unresectable metastases of CRC and few or absent symptoms of the primary tumour are randomized 1:1 between systemic therapy only, and resection of the primary tumour followed by systemic therapy. Systemic therapy will consist of fluoropyrimidine-based chemotherapy in combination with bevacizumab. The primary objective of this study is to determine the clinical benefit in terms of overall survival of initial resection of the primary tumour. Secondary endpoints include progression free survival, surgical morbidity, quality of life and the number of patients requiring resection of the primary tumour in the control arm.DISCUSSION: The CAIRO4 study is a multicentre, randomized, phase III study that will assess the benefit of resection of the primary tumour in patients with synchronous metastatic CRC.TRIAL REGISTRATION: The CAIRO4 study is registered at clinicaltrials.gov (NCT01606098).

M3 - Conference abstract in journal

VL - 33

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 15 Suppl.

M1 - TPS3630

ER -